Ether

Ether

SCHEMBL177065

CCOCC.CC[Mg]Br

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ether SCHEMBL23725937 0.85
Ether SCHEMBL28498771 0.85 ALDH1A1 (0.37)
Ether SCHEMBL27610287 0.81 ALDH1A1 (0.35)
Ether SCHEMBL1348224 0.81
SCHEMBL6054 0.80
Ether SCHEMBL7058240 0.80
Ether SCHEMBL4774210 0.78
Water SCHEMBL1849552 0.76
Ether SCHEMBL8713692 0.76
Ether SCHEMBL10434481 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12024525-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment AGENEBIO, INC. (US) 2024-07-02 US disclosed
EP-3555100-B1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT AGENEBIO INC (US) 2023-05-10 EP disclosed
US-20230134844-A1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT AGENEBIO, INC. 2023-05-04 US disclosed
US-20230107032-A1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-04-06 US disclosed
US-11312721-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment AGENEBIO, INC. (US) 2022-04-26 US disclosed
EP-3083569-B1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT AGENEBIO INC (US) 2022-01-26 EP disclosed
US-11142529-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment AGENEBIO, INC. (US) 2021-10-12 US disclosed
US-20210253588-A1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT AGENEBIO, INC. 2021-08-19 US disclosed
EP-3810611-A1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT Agenebio, Inc. (US) 2021-04-28 EP disclosed
US-20210009602-A1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT HAGER BIOSCIENCES 2021-01-14 US disclosed
CN-1340053-A Epoxicone derivative, preparation method and pharmaceutical application thereof SCHERING AG (DE) 2002-03-13 CN disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed
CN-1166169-A Heterocyclic compounds, useful as allosteric effectors at muscarinic receptors SANKYO CO (JP) 1997-11-26 CN disclosed
US-5510536-A Production method of tris(pentafluorophenyl)borane using pentafluorophenylmagnesium derivatives prepared from pentafluorobenzene TOSOH AKZO CORPORATION (JP) 1996-04-23 US disclosed
CN-1029683-C Process for preparing new steroids substituted at position 10 by a radical including a double or triple bond ROUSSEL UCLAF (FR) 1995-09-06 CN disclosed
EP-0604963-A1 Production method of tris(pentafluorophenyl)borane using pentafluorophenylmagnesium derivatives prepared from pentafluorobenzene TOSOH AKZO CORPORATION (JP) 1994-07-06 EP disclosed
CN-1037151-A The method for preparing beta-lactam derivatives ERBA CARLO SPA (IT) 1989-11-15 CN disclosed
CN-85106995-A Process for preparing new steroids substituted in the ten position by groups containing double or triple bonds 1987-04-01 CN disclosed